Ozempic Linked To Lower Cardiovascular Risk Than Mounjaro In Huge New Real-World Study
Ozempic vs Mounjaro: New Study Finds Lower Cardiovascular-Event Risk With Semaglutide
Ozempic vs Mounjaro Heart Risk
A huge real-world analysis has put cardiovascular risk at the centre of the Ozempic-Mounjaro rivalry.
Novo Nordisk says adults with type 2 diabetes who increased their weekly semaglutide dose from 1 mg to 2 mg had a statistically significant 6 per cent lower risk of major adverse cardiovascular events than comparable patients who switched to tirzepatide, the active ingredient in Mounjaro.
The finding comes from a retrospective study of claims data covering 636,525 adults with type 2 diabetes. It was presented at the European Association for the Study of Diabetes annual meeting in Milan on 29 September 2026.
That makes it one of the largest direct real-world comparisons yet of what happens after patients already taking semaglutide reach a treatment decision: stay with semaglutide and increase the dose, or switch to tirzepatide.
The result is striking. It is also narrower than the simplest headline suggests.
What The Study Actually Compared
The study, called COMPETE SWITCH CV, did not randomly assign people to Ozempic or Mounjaro.
Instead, researchers examined routine healthcare data for adults with type 2 diabetes who were already using semaglutide 1 mg. They then compared cardiovascular outcomes between patients whose treatment was escalated to semaglutide 2 mg and those who switched to tirzepatide, which can be prescribed at doses up to 15 mg.
The main endpoint was major adverse cardiovascular events, generally described as a composite involving cardiovascular death, heart attack and stroke.
Novo Nordisk said the semaglutide 2 mg group had a 6 per cent lower risk of these events than the group switching to tirzepatide.
The size of the database matters. More than 636,000 people gives researchers substantial statistical power and reflects what happens outside the controlled environment of a clinical trial.
But size alone does not turn an observational study into a randomised trial.
Doctors do not switch or escalate medicines at random. Patients moved to another drug may differ in ways that are difficult to capture completely in insurance claims or electronic records. Their weight, diabetes control, previous response, side effects, adherence, cardiovascular history, access to medicines and prescribing preferences can all influence treatment decisions.
Statistical adjustment can reduce those differences. It cannot guarantee that every important difference has disappeared.
Why The 6 Per Cent Figure Matters
A 6 per cent relative reduction is not an enormous effect, but cardiovascular outcomes matter because heart attack and stroke remain major causes of illness and death among people with type 2 diabetes.
The result is also commercially important.
Semaglutide and tirzepatide sit at the centre of one of the fiercest pharmaceutical contests in the world. Ozempic and Mounjaro are approved for type 2 diabetes, while related formulations of the same molecules are used for obesity treatment.
Much of the public conversation has focused on weight loss. Tirzepatide has repeatedly produced greater average weight reduction than semaglutide in direct weight-management comparisons.
Cardiovascular protection is a different question.
Semaglutide already has a substantial cardiovascular evidence base. In the SELECT randomised trial, semaglutide reduced the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke by 20 per cent compared with placebo in people with overweight or obesity and established cardiovascular disease who did not have diabetes.
Other randomised semaglutide trials in type 2 diabetes have also shown reductions in major cardiovascular events compared with placebo.
That does not automatically mean semaglutide is superior to tirzepatide. Comparing two active drugs is harder than showing that one drug works better than placebo.
The Wider Evidence Is Not One-Sided
This is where the new finding needs context.
A 2025 Nature Medicine study comparing semaglutide and tirzepatide in ordinary clinical practice found broadly similar risks for major cardiovascular outcomes between the two drugs. For individual outcomes including all-cause mortality, heart attack and stroke, the confidence intervals were compatible with little or no meaningful difference.
Then, in July 2026, a separate large target-trial emulation published in JACC: Advances reached a different conclusion. In that analysis of 217,920 matched adults, tirzepatide was associated with lower rates of several cardiovascular and cerebrovascular outcomes than semaglutide, including heart failure, atrial fibrillation, heart attack and stroke-related endpoints.
A 2026 systematic review and meta-analysis added another layer. It found a more consistent cardiovascular-benefit signal for semaglutide across randomised trials, while evidence for tirzepatide remained less mature. The authors specifically warned that most of the evidence came from separate drug-versus-control trials and should not be treated as definitive proof that one medicine is superior to the other.
In other words, the evidence is moving quickly, but it is not moving in one perfectly straight line.
Different studies examine different patients, different doses, different endpoints and different periods of follow-up. Some compare people starting treatment. Others examine people switching. Some focus on cardiovascular disease. Others include broader populations.
Those differences can materially change the answer.
Ozempic And Mounjaro Are Not Interchangeable Experiments
Semaglutide and tirzepatide are often discussed as if they are simply rival versions of the same drug.
They are related, but they are not identical.
Semaglutide primarily activates the glucagon-like peptide-1 receptor. Tirzepatide acts on both the GLP-1 and glucose-dependent insulinotropic polypeptide receptors.
Both can lower blood glucose, reduce appetite and produce substantial weight loss. Both also affect several cardiovascular risk factors, including blood pressure, inflammation, glucose control and body weight.
The biological question is whether those overlapping effects translate into different rates of actual cardiovascular events over years.
That requires outcome data, not simply changes in weight or cholesterol.
Tirzepatide also now has direct cardiovascular-outcome evidence of its own. The large SURPASS-CVOT programme compared tirzepatide with dulaglutide in people with type 2 diabetes and established cardiovascular disease. Tirzepatide was non-inferior for major cardiovascular events, meaning it did not perform worse than the established comparator beyond the trial’s specified margin.
That is important evidence, but it still does not provide a definitive randomised answer to semaglutide versus tirzepatide.
What Patients Should Not Conclude From This
The new study does not show that everyone taking Mounjaro should switch to Ozempic.
It does not show that semaglutide is better for weight loss.
It does not prove that semaglutide will prevent a heart attack or stroke in any individual patient.
And it does not replace the need to consider blood glucose control, weight, kidney function, existing cardiovascular disease, side effects, treatment availability and personal medical history.
The comparison is specifically about adults with type 2 diabetes who were already taking semaglutide 1 mg and then either increased to 2 mg or switched to tirzepatide.
That is a clinically relevant population. It is not every person considering either medicine.
Why Real-World Evidence Still Matters
Randomised controlled trials remain the strongest method for deciding whether a treatment causes a difference in outcomes because randomisation helps balance measured and unmeasured patient characteristics.
Real-world studies answer a different question.
They can show what happens when hundreds of thousands of people use medicines in normal clinical practice, with all the imperfect adherence, switching, dose changes and prescribing decisions that real medicine involves.
That makes the COMPETE SWITCH CV result useful.
It is evidence from a very large population suggesting that increasing semaglutide to 2 mg may preserve or improve cardiovascular protection compared with moving to tirzepatide in some adults with type 2 diabetes.
It is not the final word.
That distinction matters because GLP-1 medicines are already influencing behaviour far beyond the clinic, from food consumption to retail demand. As the drugs become more widely used, the question is shifting from whether they help people lose weight to which treatment offers the best long-term balance of metabolic, cardiovascular and practical benefits.
The newest study gives semaglutide another favourable cardiovascular signal.
The harder question — whether Ozempic is genuinely better than Mounjaro at preventing major cardiovascular events across comparable patients — remains open.
Sources
Novo Nordisk — EASD 2026 Scientific Programme And COMPETE SWITCH CV Presentation — Confirms the COMPETE SWITCH CV presentation comparing semaglutide 2.0 mg escalation with switching to tirzepatide at EASD 2026.
Reuters — Novo Says Ozempic Shows Lower Risk Of Cardiovascular Events Compared To Lilly’s Mounjaro — Reports the 636,525-patient analysis and the statistically significant 6 per cent lower MACE risk announced on 29 September 2026.
Nature Medicine — Cardiovascular Outcomes Of Semaglutide And Tirzepatide For Patients With Type 2 Diabetes In Clinical Practice — Provides independent comparative real-world evidence showing broadly similar risks for several major cardiovascular outcomes.
Next Reads
The Ozempic Effect: How Weight-Loss Drugs Are Shrinking Food Demand — Explains how GLP-1 medicines such as semaglutide and tirzepatide are changing appetite, spending and the wider food economy.
